Despite the FDA's complete response letter for MDMA-assisted psychotherapy, researchers believe the data behind this PTSD treatment is what matters most.
Ingmar Gorman, PhD
Advertisement
Dr Gorman is a study therapist in the phase 3 clinical trial for MDMA-assisted therapy and a co-founder of Fluence, a psychedelic education company that trains mental health providers in psychedelic treatments.
Articles by Ingmar Gorman, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Increased Risk of Death in Patients With Dementia Found Related to Common Hospice Medications
2
Treating Mental Illness During Pregnancy the Same as Any Medical Illness: In Conversation With Jennifer L. Payne, MD
3
The Use of Aripiprazole for Bipolar Disorder
4
FDA Accepts NDA for CTx-1301 for Treatment of ADHD
5
